Antibiotic management of lung infections in cystic fibrosis: I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections

Annals of the American Thoracic Society

Volumn 11, Issue 7, 2014, Pages 1120-1129

  Chmiel, James F ^a   Aksamit, Timothy R ^b   Chotirmall, Sanjay H ^c,d   Dasenbrook, Elliott C ^e   Elborn, J Stuart ^f   LiPuma, John J ^g   Ranganathan, Sarath C ^h   Waters, Valerie J ⁱ   Ratjen, Felix A ^j  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c BEAUMONT HOSPITAL   (Ireland)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ Division of Infectious Diseases   (Canada)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

Burkholderia cepacia; Methicillin resistant Staphylococcus aureus; Microbiome; Pseudomonas aeruginosa; Stenotrophomonas maltophilia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; FOSFOMYCIN; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER; ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SALIVA LEVEL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROBIAL COMMUNITY; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; ADULT; CHILD; COMPLICATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MICROFLORA; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; CHILD; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; EVIDENCE-BASED MEDICINE; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIOTA; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84911906189     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201402-050AS     Document Type: Article

References (82)

1. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27.
2. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-657.
3. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir Res 2003;4:8-21.
4. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177: 995-1001.
5. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011;66: 579-584.
6. LiPuma J. The new microbiology of cystic fibrosis: it takes a community. Thorax 2012;67:851-852.
7. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2012;11:CD009528.
8. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182:627-632.
9. Döring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
10. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-479.
11. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
12. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al.; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969.
13. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-689.
14. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 2010;5:e11044.
15. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 2012;7:e45001.
16. Guss AM, Roeselers G, Newton IL, Young CR, Klepac-Ceraj V, Lory S, Cavanaugh CM. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011;5:20-29.
17. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007;104:20529-20533.
18. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ, et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 2010;12:1293-1303.
19. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004;42: 5176-5183.
20. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008;105:15070-15075.
21. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012;67:867-873.
22. van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, Carroll MP, Parkhill J, Bruce KD. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J 2011;5:780-791.
23. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012;109:5809-5814.
24. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol 2012;194:4709-4717.
25. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006;44:2601-2604.
26. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012;3:e00251-12.
27. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML, Fligner CL, Singh PK. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012; 109:13769-13774.
28. Carmody LA, Zhao J, Schloss PD, Petrosino JF, Murray S, Young VB, Li JZ, LiPuma JJ. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 2013;10:179-187.
29. Cystic Fibrosis Foundation. Patient registry 2012 annual data report. Bethesda, MD; 2013.
30. Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011;10:298-306.
31. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386-2392.
32. 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-821.
33. Lo DK, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2013;2:CD009650.
34. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-292.
35. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148-1155.
36. Zobell JT, Epps K, Young DC, Hatch M, Olson J, Ampofo K, Chin M, Marshall B, Dasenbrook EC. Utilization of antibiotics for methicillinresistant Staphylococcus aureus infection in cystic fibrosis patients. Pediatr Pulmonol 2013;48:311.
37. Santos RP, Prestidge CB, Brown ME, Urbancyzk B, Murphey DK, Salvatore CM, Jafri HS, McCracken GH Jr, Ahmad N, Sanchez PJ, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009;44:148-154.
38. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother 2011;55:3393-3398.
39. U.S. Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. 2011 Jul 26 [accessed 2013 Nov 15]. Available from: http://www.fda.gov/Drugs/ DrugSafety/ucm265305.htm
40. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AM, Rudin SD, Hujer KM, Perreten V, Rice LB, et al. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother 2011;55:1684-1692.
41. Doe SJ, McSorley A, Isalska B, Kearns AM, Bright-Thomas R, Brennan AL, Webb AK, Jones AM. Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 2010;9:104-109.
42. Rifampin [package insert]. Cincinnati, OH: Pantheon Pharmaceuticals Inc; 2004.
43. Di Sant'Agnese PE, Andersen DH. Celiac syndrome: chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas: observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61.
44. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012;185:171-178.
45. Generali J, Cada D. Off-label drug uses: vancomycin: aerolsolizaton. Hosp Pharm 2004;39:638-647.
46. Jennings MJ, Boyle MP, Bucur C, Konstan MW, Dasenbrook EC. Pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis. Pediatr Pulmonol 2012;47:320.
47. Savara, Inc. Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. Clinicaltrials.Gov. NLM identifier: NCT01746095. Bethesda, MD: National Library of Medicine (US). 2012 [accessed 2014 Jan 20]. Available from: http://clinicaltrials.Gov/ ct2/show/nct01746095
48. Boyle MP. Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP). Clinicaltrials.Gov. NLM identifier: NCT01594827. Bethesda, MD: National Library of Medicine (US). 2012 [accessed 2014 Jan 20]. Available from: http://clinicaltrials. Gov/ct2/show/nct01594827
49. Muhlebach M. Early methicillin-resistant Staphylococcus aureus (MRSA) therapy in cystic fibrosis (CF) (STAR-Too). Clinicaltrials.Gov. NLM identifier: NCT01349192. Bethesda, MD: National Library of Medicine (US). 2011 [accessed 2014 Jan 20]. Available from: http://clinicaltrials.Gov/ct2/show/nct01349192
50. Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 2004;59:334-336.
51. Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, Lipuma JJ. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008;8:1025-1030.
52. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017.
53. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107:382-387.
54. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013;12: 482-486.
55. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011;183:635-640.
56. Waters V. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des 2012;18:696-725.
57. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: CLSI; 2012.
58. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55:2636-2640.
59. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-313.
60. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
61. Moriarty TF, McElnay JC, Elborn JS, Tunney MM. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007;42:1008-1017.
62. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57:306-311.
63. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001;41:645-654.
64. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al.; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68:818-825.
65. Canis F, Husson MO, Turck D, Vic P, Launay V, Ategbo S, Vincent A, Courcol RJ. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. J Antimicrob Chemother 1997;39:431-433.
66. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001;120:118S-123S.
67. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10:54-61.
68. Ratjen A, Yau Y, Wettlaufer J, Matukas L, Ratjen F, Zlosnik J, Speert DP, Tullis E, Waters V. Tobramycin susceptibilities of Burkholderia cepacia complex isolates from pediatric and adult cystic fibrosis patients. Pediatr Pulmonol 2013;31837.
69. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, Larosa M, Knoop C, McElvaney N, Lewis SA, et al.; For the AZLI Active Comparator Study Group. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros (In press)
70. Tullis DE, Burns JL, Retsch-Bogart GZ, Bresnik M, Henig NR, Lewis SA, Lipuma JJ. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014;13: 296-305.
71. Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, Hilliard GM, Parvatiyar K, Kamani MC, Wozniak DJ, et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002;54:1425-1443.
72. Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O'Toole GA. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 2012;67:2673-2681.
73. Waters V, Ratjen F, Tullis E, Corey M, Matukas L, Leahy R, Yau Y. Randomized double blind controlled trial of the use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy in chronic Pseudomonas aeruginosa infected cystic fibrosis patients. Pediatr Pulmonol 2010;330.
74. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-1516.
75. Wu K, Yau YC, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2013;57: 1546-1548.
76. Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS Immunol Med Microbiol 2011;61:141-146.
77. McCaughey G, Gilpin D, Elborn J, Tunney MM. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev Respir Med 2013;7:385-396.
78. Pattison SH, Rogers GB, Crockard M, Elborn JS, Tunney MM. Molecular detection of CF lung pathogens: current status and future potential. J Cyst Fibros 2013;12:194-205.
79. Foweraker JE, Govan JR. Antibiotic susceptibility testing in early and chronic respiratory infections with Pseudomonas aeruginosa. J Cyst Fibros 2013;12:302.
80. Gillham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother 2009;63:728-732.
81. Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012;11:288-292.
82. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012;141:485-493.